Management of Neonatal Jaundice

Immediate Assessment and Risk Stratification

The American Academy of Pediatrics recommends that a total bilirubin level of 17.5 mg/dL in a 3-day-old newborn requires prompt attention, as it is approaching the phototherapy threshold for most term infants 1, 2
A bilirubin level of 17.5 mg/dL in a 3-day-old newborn is above the 95th percentile for age and requires evaluation for underlying causes 3
Risk assessment should include gestational age, with 39 weeks being more favorable than less than 38 weeks 4
The American Academy of Pediatrics suggests that feeding method, with bottle feeding carrying lower risk than exclusive breastfeeding, should be considered in risk assessment 4
The American Academy of Pediatrics also recommends considering race, with Black race carrying lower risk, in risk assessment 1
The presence of hemolysis, indicated by a rapid rise in bilirubin levels, should be evaluated, with a rise of more than 0.2 mg/dL/hour after 24 hours suggesting hemolysis 2

The American Academy of Pediatrics recommends rechecking bilirubin levels within 4-24 hours for a 3-day-old newborn with a total bilirubin of 17.5 mg/dL 1, 2
For infants with risk factors for neurotoxicity or rapidly rising bilirubin levels, recheck bilirubin levels within 4-12 hours 2
For stable infants with no risk factors, recheck bilirubin levels within 12-24 hours 5
The timing of follow-up should be guided by the bilirubin trajectory and the infant's clinical status 2

The American Academy of Pediatrics recommends initiating phototherapy before discharge if the total bilirubin is at or above the phototherapy threshold for age and risk category 3
Close monitoring is essential for infants with bilirubin levels approaching the treatment threshold, such as 17.5 mg/dL 5
If phototherapy is initiated, total serum bilirubin should be measured to verify efficacy after starting treatment 2

If the total bilirubin is rising rapidly or unexplained by history and physical examination, additional laboratory evaluation should include blood type and Coombs' test, complete blood count with smear, and direct or conjugated bilirubin measurement 3

The American Academy of Pediatrics recommends ensuring follow-up within 1-2 days if the infant is discharged before the bilirubin peaks, typically 3-5 days in term infants 2
Parents should receive verbal and written information about jaundice monitoring and when to seek medical attention 1
For infants with bilirubin levels near treatment thresholds, consider home or outpatient follow-up within 24 hours 2

The American Academy of Pediatrics recommends immediate phototherapy initiation and close monitoring for a 72-hour-old newborn with a bilirubin level of 289 μmol/L (17 mg/dL), as this level is above the 95th percentile for age and approaches treatment thresholds for most term infants 6
G6PD screening is particularly important, as G6PD deficiency causes 31.5% of kernicterus cases 7
The American Academy of Pediatrics suggests evaluating for underlying causes, including obtaining laboratory tests such as blood type, Coombs' test, complete blood count with smear, direct or conjugated bilirubin measurement, and reticulocyte count (optional but helpful) 6
Ensure adequate caloric intake and assess feeding adequacy, and monitor weight loss and voiding/stooling patterns in breastfed infants 6

Hemolytic disease, such as ABO/Rh incompatibility and G6PD deficiency, is a major risk factor for elevated bilirubin levels 6
Cephalohematoma or significant bruising is also a risk factor for elevated bilirubin levels 6

Do not rely on visual assessment alone—always measure bilirubin levels, especially in darkly pigmented infants 6
Do not discharge without ensuring appropriate follow-up, particularly if risk factors are present 6